Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Randomized Study to Evaluate the Radiographic Efficacy and Safety of Enbrel (Etanercept) added to Methotrexate in Comparison with Usual Treatment in Subjects with Moderate Rheumatoid Arthritis Disease Activity.

Trial Profile

An Open-Label, Randomized Study to Evaluate the Radiographic Efficacy and Safety of Enbrel (Etanercept) added to Methotrexate in Comparison with Usual Treatment in Subjects with Moderate Rheumatoid Arthritis Disease Activity.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 29 Dec 2012

At a glance

  • Drugs Etanercept (Primary) ; Ciclosporin; Gold; Hydroxychloroquine; Leflunomide; Methotrexate; Methotrexate; Methotrexate; Sulfasalazine
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms EXTRA
  • Sponsors Pfizer; Wyeth
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 10 Mar 2012 The trial status is recruiting in (Spain, France, United Kingdom), completed in (Denmark) as reported by European Clinical Trials Database.
    • 20 Jun 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top